Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel

AAPS PharmSciTech

Volumn 10, Issue 4, 2009, Pages 1444-1451

  Maragos, Stratos ^a   Archontaki, Helen ^a   MacHeras, Panos ^a   Valsami, Georgia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biopharmaceutics classification; Cyclodextrins; Inclusion complex formation; Praziquantel; Solubility enhancement; Solubility dose ratio

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; POVIDONE; PRAZIQUANTEL;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; SOLID STATE; ULTRAVIOLET SPECTROSCOPY;

ANTHELMINTICS; BETA-CYCLODEXTRINS; CALIBRATION; DRUG STABILITY; DRUG STORAGE; PRAZIQUANTEL; SOLUBILITY;

EID: 75549086502     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9346-7     Document Type: Article

References (28)

1. G Amidon H Lennarnas V Shah J Crison 1995 A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 413 429 10.1023/A:1016212804288 1:CAS:528:DyaK2MXksVGqur8%3D 7617530
2. FDA/CDER, Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. Washington D.C., August 2000.
3. E Rinaki G Valsami P Macheras 2003 Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio Pharm Res 20 1917 1925 10.1023/B:PHAM.0000008037.57884.11 1:CAS:528:DC%2BD3sXpvVShsLg%3D 14725354 (Pubitemid 38005521)
4. E Rinaki A Dokoumetzidis P Macheras 2003 The mean dissolution time depends on dose/solubility ratio Pharm Res 20 406 408 10.1023/A:1022652004114 1:CAS:528:DC%2BD3sXhslGrtr4%3D 12669960 (Pubitemid 36288369)
5. C Gu H Li J Levons K Lentz R Gandhi K Raghavan R Smith 2007 Predicting effect of food on extent of drug absorption based on physicochemical properties Pharm Res 24 1118 1130 10.1007/s11095-007-9236-1 1:CAS:528:DC%2BD2sXlsVGns70%3D 17385020 (Pubitemid 46798891)
6. WHO. Report of the WHO informal consultation on the use of Praziquantel during pregnancy/lactation and Albendazole/Mebendazole in children under 24 months. Geneva: WHO; 2002.
7. WHO. Prevent ion and control of schistosomiasis and soil-transmitted helminthiasis. Geneva: WHO; 2002.
8. M Linderberg S Kopp J Dressman 2004 Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system Eur J Biopharm 58 265 278 10.1016/j.ejpb.2004.03.001 (Pubitemid 39037234)
9. N Kasim M Whitehouse C Ramachandran M Bermejo H Lennernas A Hussain, et al. 2004 Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Molecular Pharmaceutics 1 85 96 10.1021/mp034006h 1:CAS:528:DC%2BD3sXpvVSmsb8%3D 15832504
10. Duchêne D (ed) Cyclodextrins and their industrial uses. Editions de Santé, Paris, France; 1987.
11. M Brewster T Loftsson 2007 Cyclodextrins as pharmaceutical solubilizers Adv Drug Del Rev 59 645 666 10.1016/j.addr.2007.05.012 1:CAS:528: DC%2BD2sXpsFGks7g%3D (Pubitemid 47299263)
12. T Loftsson D Duchene 2007 Cyclodextrins and their pharmaceutical applications Int J Pharm 329 1 11 10.1016/j.ijpharm.2006.10.044 1:CAS:528:DC%2BD28XhtlCmtLrF 17137734 (Pubitemid 44937538)
13. S Gould RC Scott 2005 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review Food Chem Toxicol 43 1451 1459 10.1016/j.fct.2005.03.007 1:CAS:528:DC%2BD2MXmt1eiu78%3D 16018907 (Pubitemid 40961909)
14. T Loftsson 1998 Increasing the cyclodextrin complexion of drugs and drug bioavailability through addition of water-soluble polymers Pharmazie 53 733 740 1:CAS:528:DyaK1cXnslKlurk%3D 9853355
15. T Loftsson M Masson 2004 The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs J Drug Del Sci Tech 14 35 43 1:CAS:528:DC%2BD2cXks1Kgtrw%3D
16. T Loftsson 2002 Cyclodextrins and the biopharmaceutics classification system of drugs J Inc Phen Macroc Chem 44 63 67 10.1023/A:1023088423667 1:CAS:528:DC%2BD3sXkvFCqtLY%3D (Pubitemid 38075665)
17. K Uekama 2004 Design and evaluation of cyclodextrin-based drug formulation Chem Pharm Bull 52 900 915 10.1248/cpb.52.900 1:CAS:528: DC%2BD2cXmvVKktbg%3D 15304981 (Pubitemid 41701863)
18. G Becket L Schep M-Y Tan 1999 Improvement of the in vitro dissolution of praziquantel by complexation with α-, β- and γ-cyclodextrins Int J Pharm 179 65 71 10.1016/S0378-5173(98)00382-2 1:CAS:528:DyaK1MXhsVensL0%3D 10053203 (Pubitemid 29115061)
19. 1H- nuclear magnetic resonance J Pharm Biomed Anal 41 1428 1432 10.1016/j.jpba.2006. 03.010 16678375 (Pubitemid 44218690)
20. S El-Arini H Leuenberger 1996 Dissolution properties of praziquantel-cyclodextrin systems Pharm Dev Techn 1 307 315 10.3109/ 10837459609022600 1:CAS:528:DyaK28Xms1aktrw%3D
21. T Higuchi K Connors 1965 Phase-solubility techniques Adv Αnal Chem Instr 4 117 212 1:CAS:528:DyaF2MXktlGitrg%3D
22. M Vertzoni Th Kartezini H Archontaki Ch Reppas G Valsami 2006 Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems Int J Pharm 309 115 122 10.1016/j.ijpharm.2005.11. 021 1:CAS:528:DC%2BD28XnvVWhtA%3D%3D 16376501 (Pubitemid 43129473)
23. S El-Arini H Leuenberger 1998 Dissolution properties of praziquantel-PVP systems Pharm Acta Helv 7 89 94 10.1016/S0031-6865(97)00051-4 (Pubitemid 28327970)
24. T Loftsson M Masson M Brewster 2004 Self-association of cyclodextrins and cyclodextrin complexes: minireview J Pharm Sci 93 1091 1099 10.1002/jps.20047 1:CAS:528:DC%2BD2cXjsFKisLo%3D 15067686 (Pubitemid 38529683)
25. G Dinora R Julio C Nelly Y Lilian H Cook 2005 In vitro characterization of some biopharmaceutical properties of praziquantel Int J Pharm 295 93 99 10.1016/j.ijpharm.2005.01.033 1:CAS:528:DC%2BD2MXjtl2rs7Y%3D (Pubitemid 40558792)
26. S El-Arini D Giron H Leuenberger 1998 Solubility properties of racemic praziquantel and its enantiomers Pharm Dev Technol 3 557 564 10.3109/10837459809028638 1:CAS:528:DyaK1cXnsFemt7w%3D 9834959
27. EMEA draft guideline on the investigation of bioequivalence, 24 July, 2008.
28. M Valero P Mura 2003 Effect of PVP-25 on the formation of the naproxen:β-cyclodextrin complex Int J Pharm 253 97 110 10.1016/S0378- 5173(02)00664-6 1:CAS:528:DC%2BD3sXht1Wmsbs%3D 12593941 (Pubitemid 36197835)